Anticoagulation in an Older Adult With Falls and CKD
An 82-year-old woman with atrial fibrillation, stage 4 chronic kidney disease (eGFR 22 mL/min/1.73 m2), hypertension, and two falls in the past six months presents for medication review. She takes apixaban 5 mg twice daily, metoprolol, amlodipine, and occasional ibuprofen for knee pain. Her CHA2DS2-VASc score is 5 and HAS-BLED is 3. She lives alone, uses a walker, and her daughter visits weekly. She asks whether she should stop the blood thinner because of the falls. Labs: hemoglobin 10.8 g/dL, platelets 180, creatinine 2.4 mg/dL.
1. How should the NP weigh stroke prevention against bleeding and fall risk?
Read the worked answer
The decision should be framed around absolute risk reduction, not the fear of a single fall. With a CHA2DS2-VASc of 5, untreated stroke risk is high, and atrial fibrillation-related strokes are often severe. Falls are common but the absolute risk of a fatal intracranial hemorrhage attributable to anticoagulation is lower than the stroke risk avoided for most older adults. The NP should not stop anticoagulation reflexively; instead, address modifiable bleeding risks: discontinue ibuprofen, which raises GI bleeding risk and is nephrotoxic in CKD; review doses; treat anemia; assess gait, vision, home hazards, and orthostatic blood pressure; and consider fall prevention. HAS-BLED of 3 flags the need for closer monitoring and correction of reversible factors, not automatic discontinuation. Shared decision-making should include the patient's values and her daughter's input, with documentation of the rationale.
2. Is the current apixaban dose appropriate, and what alternatives exist?
Read the worked answer
Apixaban dose reduction to 2.5 mg twice daily is criteria-based: age 80 or older, weight 50 kg or less, or creatinine 1.5 mg/dL or higher, with at least two criteria required. This patient is 82 and has creatinine 2.4, so she meets two criteria and dose reduction should be considered, but the NP must verify weight and confirm the label criteria rather than dose by creatinine alone. Renal function should be reassessed periodically because CKD is progressive. Alternatives include warfarin, which is less convenient and requires INR monitoring but may be considered in severe CKD depending on local guidance, or another direct oral anticoagulant with renal dosing adjustments. The NP should avoid combining antiplatelets without a clear indication. Ibuprofen should be stopped and knee pain managed with acetaminophen, topical agents, or physical therapy. Any change requires follow-up labs and a clear monitoring plan.
3. What patient education and monitoring plan should be documented?
Read the worked answer
Education should cover: why the anticoagulant is continued (stroke prevention), signs of bleeding (black stools, unusual bruising, nosebleeds that do not stop, confusion or severe headache suggesting intracranial bleed), and when to call 911. Emphasize avoiding NSAIDs and over-the-counter combination products, and check with the NP before starting new medicines or supplements. Fall prevention: review home safety, footwear, vision, and use of the walker; discuss orthostatic precautions. Monitoring: complete blood count and renal function at least every 3-6 months or sooner after illness, and after any bleeding event. Provide written instructions and involve the daughter with permission. Document the shared decision, the specific dose rationale, and follow-up interval. If the patient prefers to stop, document informed refusal and offer close follow-up rather than abandoning care.